

**In the Claims:**

1-27. Canceled.

28. (Currently amended) An isolated nucleic acid encoding a polypeptide having at least 80% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271);
- (b) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;
- (e) the nucleic acid sequence shown in Figure 151 (SEQ ID NO: 270);
- (f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270); or
- (g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein said encoded polypeptide is an immunosuppressor.

29. (Currently amended) An isolated nucleic acid of Claim 28 encoding a polypeptide having at least 85% nucleic acid sequence identity to:

- (a) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271);
- (b) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;

- (e) the nucleic acid sequence shown in Figure 151 (SEQ ID NO: 270);
- (f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270); or
- (g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein said encoded polypeptide is an immunosuppressor.

30. (Currently amended) An isolated nucleic acid of Claim 28 encoding a polypeptide having at least 90% ~~nucleic acid~~ sequence identity to:

- (a) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271);
- (b) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;
- (c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271);
- (d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;
- (e) the nucleic acid sequence shown in Figure 151 (SEQ ID NO: 270);
- (f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270); or
- (g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein said encoded polypeptide is an immunosuppressor.

31. (Currently amended) An isolated nucleic acid of Claim 28 encoding a polypeptide having at least 95% ~~nucleic acid~~ sequence identity to:

- (a) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271);
- (b) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;

- (e) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;~~
- (e) ~~the nucleic acid sequence shown in Figure 151 (SEQ ID NO: 270);~~
- (f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270); or
- (g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein said encoded polypeptide is an immunosuppressor.

32. (Currently amended) An isolated nucleic acid of Claim 28 encoding a polypeptide having at least 99% ~~nucleic acid~~ sequence identity to:

- (a) ~~a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271);~~
- (b) ~~a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;~~
- (e) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;~~
- (e) ~~the nucleic acid sequence shown in Figure 151 (SEQ ID NO: 270);~~
- (f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270); or
- (g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein said encoded polypeptide is an immunosuppressor.

33. (Currently amended) An isolated nucleic acid comprising:

- (a) a nucleic acid sequence encoding the polypeptide of shown in Figure 152 (SEQ ID NO: 271);
- (b) a nucleic acid sequence encoding the polypeptide of shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;
- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide of shown in Figure 152 (SEQ ID NO: 271);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide;~~
- (e)(c) the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270);
- (f)(d) the full-length coding sequence of the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270); or
- (g)(e) the full-length coding sequence of the cDNA deposited under ATCC accession number 203277.

34. (Currently amended) The isolated nucleic acid of Claim 33 comprising a nucleic acid sequence encoding the polypeptide of shown in Figure 152 (SEQ ID NO: 271).

35. (Currently amended) The isolated nucleic acid of Claim 33 comprising a nucleic acid sequence encoding the polypeptide of shown in Figure 152 (SEQ ID NO: 271), lacking its associated signal peptide.

36-37. Canceled.

38. (Currently amended) The isolated nucleic acid of Claim 33 comprising the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270).

39. (Currently amended) The isolated nucleic acid of Claim 33 comprising the full-length coding sequence of the nucleic acid sequence of shown in Figure 151 (SEQ ID NO: 270).

40. (Previously presented) The isolated nucleic acid of Claim 33 comprising the full-length

coding sequence of the cDNA deposited under ATCC accession number 203277.

41-43. (Canceled)

44. (Currently amended) A vector comprising the nucleic acid of Claim 28, 48 or 53.
45. (Previously presented) The vector of Claim 44, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.
46. (Previously presented) A host cell comprising the vector of Claim 44.
47. (Previously presented) The host cell of Claim 46, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.
48. (New) An isolated nucleic acid encoding a polypeptide having at least 80% sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO: 271;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO: 271, lacking its associated signal peptide;
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 270; or
  - (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein the nucleic acid encoding said polypeptide is amplified in lung or colon tumors or wherein said encoded polypeptide induces chondrocyte proliferation.
49. (New) An isolated nucleic acid encoding a polypeptide having at least 85% sequence identity to:
  - (a) the amino acid sequence of the polypeptide of SEQ ID NO: 271;

- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 271, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 270; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein the nucleic acid encoding said polypeptide is amplified in lung or colon tumors or wherein said encoded polypeptide induces chondrocyte proliferation.

50. (New) An isolated nucleic acid encoding a polypeptide having at least 90% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 271;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 271, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 270; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;  
wherein the nucleic acid encoding said polypeptide is amplified in lung or colon tumors or wherein said encoded polypeptide induces chondrocyte proliferation.

51. (New) An isolated nucleic acid encoding a polypeptide having at least 95% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 271;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 271, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 270; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277;

wherein the nucleic acid encoding said polypeptide is amplified in lung or colon tumors or wherein said encoded polypeptide induces chondrocyte proliferation.

52. (New) An isolated nucleic acid encoding a polypeptide having at least 99% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 271;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 271, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 270; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203277; wherein the nucleic acid encoding said polypeptide is amplified in lung or colon tumors or wherein said encoded polypeptide induces chondrocyte proliferation.

53. (New) An isolated nucleic acid molecule at least 30 nucleotides in length that hybridizes under stringent conditions to:

- (a) the nucleic acid sequence of SEQ ID NO: 270 or a complement thereof;
- (b) the full-length coding sequence of the cDNA deposited under ATCC accession number 203277 or a complement thereof;

wherein, said stringent conditions use 50% formamide, 5X SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, and washes at 42°C in 0.2X SSC, at 55°C in 50% formamide followed by a high-stringency wash at 55°C in 0.1X SSC, EDTA; and wherein said isolated nucleic acid molecule is suitable for use as a PCR primer or probe.

54. (New) The isolated nucleic acid molecule of Claim 53 that is at least 50 nucleotides or above in length.

55. (New) The isolated nucleic acid molecule of Claim 53 that is at least 60 nucleotides or above in length.
56. (New) The isolated nucleic acid molecule of Claim 53 that is at least 70 nucleotides or above in length.
57. (New) The isolated nucleic acid molecule of Claim 53 that is at least 80 nucleotides or above in length.
58. (New) The isolated nucleic acid molecule of Claim 53 that is at least 90 nucleotides or above in length.
59. (New) The isolated nucleic acid molecule of Claim 53 that is at least 100 nucleotides or above in length.